Hefei Hengxin Life Science and Technology
301501
Triductor Technology
688259
Zhejiang Sf Oilless Bearing Co.,Ltd.
300817
4
Shenzhen Riland Industry Group
300154
5
Chengdu TangYuan Electric
300789
US Stock MarketDetailed Quotes
ACHV Achieve Life
- 2.780
- -0.130-4.47%
Close Mar 18 16:00 ET
96.42MMarket Cap-2.24P/E (TTM)
2.960High2.770Low86.16KVolume2.950Open2.910Pre Close242.61KTurnover0.29%Turnover RatioLossP/E (Static)34.69MShares5.59052wk High4.61P/B81.84MFloat Cap2.51052wk Low--Dividend TTM29.44MShs Float1856247.281Historical High--Div YieldTTM6.53%Amplitude2.000Historical Low2.815Avg Price1Lot Size
Trending Stocks
Discussing
Tesla's earnings caused fluctuations, what's your market outlook？
Tesla's Q4 2024 revenue was $25.71 billion, up 2% year-on-year but below expectations. Can Tesla's stock price keep rising in 2025 with Trum
Moo Earnings
Jan 24 10:26
TSLA earnings preview: Grab rewards by guessing the opening price!
Achieve Life Stock Forum
Achieve's Smoking Cessation Drug Hits Critical FDA Safety Milestone in Phase 3 Trial
Achieve Life Sciences Announces Positive Outcome of Second Data Safety Monitoring Committee Review for the ORCA-OL Clinical Trial
Monday, 10th February at 8:30 am
No Safety Concerns Identified by DSMC in the ORCA-OL Long-Term Exposure Trial
Achieve Reiterates Planned Cytisinicline NDA Submission in Q2 2025
SEATTLE and VANCOUVER, British Columbia, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage specialty pharmaceutical company...
Achieve Life Sciences Announces Critical Milestone Successfully Reached in ORCA-OL Cytisinicline Clinical Trial Required for NDA Submission
Tuesday, 7th January at 8:30 am
Over 300 Participants Have Completed Cumulative Six Months of Cytisinicline Treatment in the ORCA-OL Trial, Completing the Long-Term Exposure Requirement for NDA Submission
ORCA-OL Long-Term Exposure Timelines Remain on Track with No Safety Concerns Identified
Planned Cytisinicline NDA Submission on...
Achieve Life Sciences Announces Initiation of ORCA-OL Clinical Trial Evaluating Long-Term Exposure of Cytisinicline in People who Smoke or Use Nicotine E-Cigarettes
Achieve Life Sciences has initiated the ORCA-OL clinical trial to evaluate the long-term safety of cytisinicline, a treatment for smoking and nicotine dependence. The open-label trial involves 29 U.S. sites and aims to collect data required for a New Drug Application (NDA) submission expected in the first ...
NEWS
Achieve Life Sciences Announces Publication of Cytisinicline Vaping Cessation Trial Results in JAMA Internal Medicine
$Taysha Gene Therapies (TSHA.US)$ 21% FY 2023 results
$TFF Pharmaceuticals (TFFP.US)$ 14% Clinical programs update
$Jaguar Health (JAGX.US)$ 14% Crofelemer commercialization
$Acelyrin (SLRN.US)$ 4% Ph1/2 positive data
$Delcath Systems (DCTH.US)$ 3% Closes $7M private placement
$Sellas Life Sciences (SLS.US)$ 0% Closes $20M offering & private placement
$Immunic (IMUX.US)$ 1% Patent notice of allowance
$Nurix Therapeutics (NRIX.US)$ 0...
No comment yet